Pulmonx
Jérôme has more than 20 years of successful healthcare management experience. He is an international executive with a focus on developing markets for breakthrough technologies. Jérôme has held roles of increasing responsibility in sales, marketing, and general management in Europe and North America. Jérôme joined Pulmonx from Covidien, where he built and led Covidien’s Vascular Therapies division as its Vice President & General Manager EMEA. Prior to this, he served as VP & GM for ev3 International, acquired by Covidien in 2011. Previously, Jérôme held P&L responsibilities at Baxter International and Celesio. Jérôme holds a Business Administration degree from ISC Paris and a Specialized Master diploma from ESCP Europe.
This person is not in any offices
Pulmonx
2 followers
Pulmonx has developed the Zephyr Endobronchial Valve, a minimally invasive treatment for COPD/emphysema. The one-time procedure is done by bronchoscopy and requires no cutting or incisions. During the procedure, on average 4 tiny valves are placed in the airways to block off the diseased parts of the lung which allows trapped air to escape until the lobe is reduced. Reducing hyperinflation allows the healthier parts of the lungs to expand and take in more air. This results in patients being able to breathe easier and have less shortness of breath.1